MX2019015516A - Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. - Google Patents

Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.

Info

Publication number
MX2019015516A
MX2019015516A MX2019015516A MX2019015516A MX2019015516A MX 2019015516 A MX2019015516 A MX 2019015516A MX 2019015516 A MX2019015516 A MX 2019015516A MX 2019015516 A MX2019015516 A MX 2019015516A MX 2019015516 A MX2019015516 A MX 2019015516A
Authority
MX
Mexico
Prior art keywords
treating cancer
binding antibodies
1beta binding
functional fragment
1beta
Prior art date
Application number
MX2019015516A
Other languages
English (en)
Inventor
Ligueros-Saylan Monica
Matchaba Patrice
Thuren Tom
Ridker Paul
Libby Peter
Ottewell Penelope
Yi Lau Yang
Dugan Margaret
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2018/054637 external-priority patent/WO2018235056A1/en
Publication of MX2019015516A publication Critical patent/MX2019015516A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Abstract

Uso de un anticuerpo de unión a IL-1ß o un fragmento funcional del anticuerpo, especialmente canakinumab o su fragmento funcional, o gevokizumab o su fragmento funcional, y biomarcadores para el tratamiento y/o la prevención del cáncer con una base inflamatoria por lo menos parcial.
MX2019015516A 2017-06-22 2018-06-22 Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. MX2019015516A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762523458P 2017-06-22 2017-06-22
US201762529515P 2017-07-07 2017-07-07
US201762550325P 2017-08-25 2017-08-25
US201762550307P 2017-08-25 2017-08-25
US201762596054P 2017-12-07 2017-12-07
US201862649631P 2018-03-29 2018-03-29
US15/970,542 US20190048072A1 (en) 2017-06-22 2018-05-03 USE OF IL-1beta BINDING ANTIBODIES
TW107115136A TW201904993A (zh) 2017-06-22 2018-05-03 IL-1β 結合抗體之用途
PCT/IB2018/053096 WO2018234879A1 (en) 2017-06-22 2018-05-03 USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
PCT/IB2018/054637 WO2018235056A1 (en) 2017-06-22 2018-06-22 IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
MX2019015516A true MX2019015516A (es) 2020-02-24

Family

ID=62530267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015516A MX2019015516A (es) 2017-06-22 2018-06-22 Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.

Country Status (17)

Country Link
US (3) US20190048072A1 (es)
EP (1) EP3642234A1 (es)
JP (4) JP2020524694A (es)
KR (2) KR20200019865A (es)
CN (1) CN110831967A (es)
AU (4) AU2018287519B2 (es)
BR (1) BR112019027558A2 (es)
CA (2) CA3061874A1 (es)
CL (1) CL2019003799A1 (es)
CO (1) CO2019014433A2 (es)
IL (1) IL271221A (es)
JO (1) JOP20190292A1 (es)
MX (1) MX2019015516A (es)
RU (1) RU2020102237A (es)
SG (1) SG11201911283UA (es)
TW (3) TW201904993A (es)
WO (1) WO2018234879A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404850SA (en) 2012-02-13 2014-09-26 Agency Science Tech & Res IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
KR20210108422A (ko) * 2018-12-21 2021-09-02 노파르티스 아게 IL-1β 결합 항체의 용도
KR20220004067A (ko) * 2019-04-01 2022-01-11 임메타스 테라퓨틱스, 인코포레이티드 종양 미세환경을 표적화하는 이중특이적 결합 분자 및 면역 체크포인트 단백질
EP3980561A1 (en) * 2019-06-06 2022-04-13 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
KR20220032076A (ko) * 2019-07-09 2022-03-15 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 Tnf-알파 및 il-1베타에 대한 이중특이적 항체 및 이의 용도
JPWO2021182573A1 (es) * 2020-03-12 2021-09-16
EP3970727A1 (en) * 2020-09-16 2022-03-23 Johann Wolfgang Goethe-Universität Frankfurt Means for reducing radiotherapy resistance and adverse effects
JPWO2022091375A1 (es) * 2020-10-30 2022-05-05
WO2022167916A1 (en) * 2021-02-03 2022-08-11 Novartis Ag Use of il-1b binding antibodies for treating neuroinflammatory disorders
WO2023038619A1 (en) * 2021-09-08 2023-03-16 Board Of Regents, The University Of Texas System USE OF IL-1β BINDING ANTIBODIES
CN115125303B (zh) * 2022-06-07 2023-02-24 北京大学第一医院 阿帕替尼药敏标记物及其相关试剂的应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
PT2314623E (pt) 2005-06-21 2012-10-02 Xoma Technology Ltd Anticorpos de ligação a il-1β e os seus fragmentos
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
JP5411430B2 (ja) 2005-07-04 2014-02-12 株式会社 ニコンビジョン 測距装置
CN102796743B (zh) 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US20090258020A1 (en) * 2008-01-07 2009-10-15 Patrys Limited Antibody designated barb3, barb3 related antibodies, and methods of making and using same
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN103951753B (zh) 2009-09-03 2018-01-12 默沙东公司 抗‑gitr抗体
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
CA2814155C (en) 2010-06-11 2019-10-22 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP6097702B2 (ja) 2011-03-03 2017-03-15 アペクシジェン， インコーポレイテッド 抗ｉｌ−６受容体抗体およびその使用方法
WO2012121679A1 (en) * 2011-03-09 2012-09-13 Agency For Science, Technology And Research Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
SG11201404850SA (en) * 2012-02-13 2014-09-26 Agency Science Tech & Res IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
TWI658051B (zh) 2013-03-15 2019-05-01 葛蘭素史密斯克藍智慧財產發展有限公司 抗原結合蛋白
EP3770176A1 (en) 2013-05-02 2021-01-27 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
HRP20220214T1 (hr) 2014-01-15 2022-04-29 Kadmon Corporation, Llc Imunomodulacijska sredstva
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JP2017505773A (ja) 2014-01-28 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血液悪性腫瘍を処置するための抗ｌａｇ−３抗体
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2770684T3 (es) 2014-03-14 2020-07-02 Novartis Ag Moléculas de anticuerpos contra LAG-3 y usos de los mismos
CN108064242B (zh) 2014-05-28 2022-10-21 阿吉纳斯公司 抗gitr抗体和其使用方法
JP6666905B2 (ja) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション Ｐｄ−ｌ１抗体及びその使用
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MX2017004311A (es) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MX2017005920A (es) 2014-11-06 2017-06-27 Hoffmann La Roche Anticuerpos anti-tim3 y metodos de uso.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CA2978892A1 (en) 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
CA2984188A1 (en) * 2015-05-12 2016-11-17 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
IL257030B2 (en) 2015-07-23 2023-03-01 Inhibrx Inc Multivalent and multispecific cleavage proteins that bind to gitr, preparations containing them and their uses
CN108025051B (zh) * 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
JP2018522571A (ja) 2015-08-12 2018-08-16 メディミューン リミテッド Ｇｉｔｒｌ融合タンパク質およびその使用

Also Published As

Publication number Publication date
AU2018288060B2 (en) 2021-07-15
CN110831967A (zh) 2020-02-21
AU2021254559A1 (en) 2021-11-18
JP2023071657A (ja) 2023-05-23
TW201904993A (zh) 2019-02-01
JP2022181214A (ja) 2022-12-07
JP2020524694A (ja) 2020-08-20
CL2019003799A1 (es) 2020-07-31
AU2021245184A1 (en) 2021-11-04
CA3066045A1 (en) 2018-12-27
TW201904995A (zh) 2019-02-01
CO2019014433A2 (es) 2020-01-17
KR20200021086A (ko) 2020-02-27
EP3642234A1 (en) 2020-04-29
CA3061874A1 (en) 2018-12-27
SG11201911283UA (en) 2020-01-30
JP2020524698A (ja) 2020-08-20
AU2018288060A1 (en) 2019-12-19
TW202400641A (zh) 2024-01-01
US20220389090A1 (en) 2022-12-08
AU2018287519A1 (en) 2019-11-07
RU2020102237A (ru) 2021-07-22
IL271221A (en) 2020-01-30
BR112019027558A2 (pt) 2020-07-21
KR20200019865A (ko) 2020-02-25
US20230220063A1 (en) 2023-07-13
US20190048072A1 (en) 2019-02-14
WO2018234879A1 (en) 2018-12-27
RU2020102237A3 (es) 2022-03-11
AU2018287519B2 (en) 2021-07-22
JOP20190292A1 (ar) 2019-12-22

Similar Documents

Publication Publication Date Title
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2020000960A (es) Anticuerpos anti-tigit.
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
EA202091540A1 (ru) Антитела к lilrb2
MX2020012607A (es) Anticuerpos especificos para gucy2c y sus usos.
WO2018031490A3 (en) Anti-ox40 binding proteins
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
MX2017001959A (es) Anticuerpos especificos para mmp9.
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
SG11202109545VA (en) Treatment employing anti-il-13r antibody or binding fragment thereof
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2018069871A3 (en) Anti-kras binding proteins
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
MX2021008216A (es) Anticuerpos anti-tigit.
MX2021007488A (es) Uso de anticuerpos il-1 beta en el tratamiento o prevencion del sindrome mielodisplasico.
HK1243439A1 (zh) Pcsk9抗體、其抗原結合片段及其醫藥用途
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
IL280421A (en) Cancer treatment by antibody